Study: Side effects emerge after approval for many US drugs

May 9, 2017 by Lindsey Tanner
This Thursday, April 8, 2005 file photo shows a bottle of Bextra at a drugstore in New York. Almost one-third of new drugs approved by FDA from 2001-2010, ended up years later with warnings about unexpected, sometimes life-threatening side effects or complications, suggested by an analysis published Tuesday, May 9, 2017, in the Journal of the American Medical Association. The painkiller Bextra was taken off the market in 2005 because of an increased risk of heart problems. (AP Photo/Mary Altaffer)

Almost one-third of new drugs approved by U.S. regulators over a decade ended up years later with warnings about unexpected, sometimes life-threatening side effects or complications, a new analysis found.

The results covered all 222 prescription drugs approved by the U.S. Food and Drug Administration from 2001 through 2010. The researchers looked at potential problems that cropped up during routine monitoring that's done once a medicine is on the market. The 71 flagged drugs included top-sellers for treating depression, arthritis, infections and blood clots. Safety issues included risks for serious skin reactions, liver damage, cancer and even death.

"The large percentage of problems was a surprise," and they included side effects not seen during the review process, said Dr. Joseph Ross, the study's lead author and an associate professor of medicine and public health at Yale University.

While most safety concerns were not serious enough to prompt recalls, the findings raise questions about how thoroughly drugs are tested before approval, said drug safety expert Thomas Moore. But Ross said the results suggest that the FDA "is kind of doing a great job" at scrutinizing drugs after approval.

New drugs are generally tested first in hundreds or even thousands of people for safety and effectiveness.

"We know that safety concerns, new ones, are going to be identified once a drug is used in a wider population. That's just how it is," Ross said. "The fact that that's such a high number means the FDA is working hard to evaluate drugs and once concerns are identified, they're communicating them."

The researchers analyzed online FDA data on new drugs and the agency's later safety announcements. Problems surfaced on average about four years after approval. Results were published Tuesday in the Journal of the American Medical Association.

The FDA said in a statement that it performs post-market monitoring "to identify new safety information that may impact product labeling." The agency said it would review the study findings but declined to comment further.

The study counted black-box warnings for dozens of drugs; these involved serious problems including deaths or life-threatening conditions linked with the drugs. There were also dozens of alerts for less serious potential harms and three drug withdrawals because of the potential for death or other serious harm.

Among the drugs with added warnings: Humira, used for arthritis and some other illnesses; Abilify, used for depression and other mental illness; and Pradaxa, a blood thinner. The withdrawn drugs and the reason: Bextra, an anti-inflammatory medicine, heart problems; Raptiva, a psoriasis drug, rare nervous system illness; and Zelnorm, a bowel illness drug, heart problems.

Safety issues were most common for psychiatric drugs and biologic drugs—made from living cells rather than chemicals—than for older drug types. Drugs brought to market through "accelerated" approval were slightly more likely to have later safety issues than those approved through conventional channels, a link seen in some previous research.

In recent years, there has been increasing pressure on the FDA from consumers and others to speed up its regulatory review process to get new drugs to the market sooner, Ross said.

Moore, a senior scientist for drug safety and policy at the Institute for Safe Medication Practices, said the new results raise concerns about whether new drugs are being extensively tested before approval. He noted that since 2011, drugs have increasingly been approved based on studies in small numbers of patients amid public criticism questioning whether the FDA is keeping potential cures away from patients.

"The answer is, you can't know whether they're valuable and lifesaving treatments unless you test them" adequately, Moore said.

PhRMA, a drug industry trade group, is reviewing the study, said spokeswoman Holly Campbell. In a statement, she said the industry is committed to post-market surveillance of new medicines, but added, "Even with rigorous clinical studies and regulatory review it may be impossible to detect certain safety signals until several years after approval, once the medicine is in broader use."

Explore further: FDA approves second near-copy of Remicade for immune disorders

Related Stories

FDA approves second near-copy of Remicade for immune disorders

April 21, 2017
Federal regulators on Friday approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.

FDA warns of potential side effects of powerful antibiotics

May 13, 2016
The U.S. Food and Drug Administration is ratcheting up its warning about the potential side effects of a type of commonly-prescribed powerful antibiotic often known by the brand name Cipro.

Safety concerns about new drugs revealed

August 4, 2014
What's safer: a newly approved drug or one that has been on the market much longer? Newer drugs have a one in three chance of acquiring a black box warning or being withdrawn for safety reasons within 25 years of their approval, ...

FDA issues anesthesia warning for pregnant women, kids under three

December 14, 2016
(HealthDay)—Repeated or lengthy use—longer than three hours—of general anesthetic and sedation drugs may harm the developing brains of fetuses and children younger than 3 years old, the U.S. Food and Drug Administration ...

Novartis wins US OK for biosimilar version of Amgen's Enbrel

August 30, 2016
U.S. regulators have approved the first near-copy of Enbrel, drugmaker Amgen's pricey biologic medicine for treating rheumatoid arthritis and other immune system disorders.

Health Canada's fast-tracked drug approvals can put public at risk

October 8, 2012
Drugs streamed into Health Canada's accelerated review process are more likely to be withdrawn from the market or earn a serious safety warning than those that undergo the standard review, according to a recent paper out ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

TheGhostofOtto1923
not rated yet May 09, 2017
"While most safety concerns were not serious enough to prompt recalls, the findings raise questions about how thoroughly drugs are tested"

-This is industry pushback against the effort to cut regs and bring lifesaving drugs to market quicker.

"The answer is, you can't know whether they're valuable and lifesaving treatments unless you test them" adequately, Moore said."

-And testing them on people desperate to live is a pretty good way isnt it?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.